ENABLING WARFARE AT THE SPEED OF LIGHT: A COMPARATIVE ANALYSIS OF MULTI-MISSION HIGH ENERGY LASER RADARS

This capstone report provides a cost effectiveness analysis of various radar systems capable of guiding the Multi-Mission High Energy Laser (MMHEL) from a Stryker platform. The Army's Rapid Capability and Critical Technologies Office (RCCTO) is developing the MMHEL to provide a Mobile Short-Range Air Defense (MSHORAD) capability to maneuver units. The MMHEL requires a radar to cue the fire control system for target engagement. Past efforts to employ high-energy lasers have relied on large, stationary radars for target acquisition. The reliance on such radars limits a unit's ability to maneuver and results in the laser being employed primarily from a defensive posture. To maximize maneuverability and enable the offensive employment of the MMHEL, the U.S. Army needs an on-platform radar that is compact and inexpensive enough to equip multiple Strykers within a Stryker Brigade Combat Team with the capability to engage targets from a mobile platform. The RCCTO is currently tasked with accelerating efforts to fill this need. The intent of this report is to assist the RCCTO in these efforts by generating a list of viable radar alternatives and conducting a cost effectiveness analysis to produce a recommendation of the most optimal solution. The results indicate that RADA's aCHR radar presents the best value in terms of cost and benefit to the warfighter.http://archive.org/details/enablingwarfarea1094564109Captain, United States ArmyCaptain, United States ArmyMajor, United States ArmyCaptain, United States ArmyCaptain, United States ArmyApproved for public release; distribution is unlimited

A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]

BACKGROUND: Decision aids are often advocated as a means to assist patient and health care provider decision making when faced with complicated treatment or screening decisions. Despite an exponential growth in the availability of decision aids in recent years, their impact on long-term treatment decisions and patient adherence is uncertain due to a paucity of rigorous studies. The choice of antithrombotic therapy for nonvalvular atrial fibrillation (NVAF) is one condition for which a trade-off exists between the potential risks and benefits of competing therapies, and the need to involve patients in decision making has been clearly identified. This study will evaluate whether an evidence-based patient decision aid for patients with NVAF can improve the appropriateness of antithrombotic therapy use by patients and their family physicians. DESIGN: A multi-center, two-armed cluster randomized trial based in community family practices in which patients with NVAF will be randomized to decision aid or usual care. Patients will receive one of four decision aids depending on their baseline stroke risk. The primary outcome is the provision of "appropriate antithrombotic therapy" at 3 months to study participants (appropriateness defined as per the 2001 American College of Chest Physicians recommendations for NVAF). In addition, the impact of this decision aid on patient knowledge, decisional conflict, well-being, and adherence will be assessed after 3 months, 6 months, and 12 months